Reverb Therapeutics is a technology company.
Reverb Therapeutics has raised $12.0M across 1 funding round.
Reverb Therapeutics has raised $12.0M in total across 1 funding round.
Reverb Therapeutics has raised $12.0M in total across 1 funding round.
Reverb Therapeutics's investors include Amplitude VC.
Reverb Therapeutics is a Vancouver-based preclinical biotechnology company developing bispecific antibodies via its AmplifyR™ platform to amplify natural cytokine signaling, targeting cancers and autoimmune diseases.[1][2][4] The platform redirects the body's endogenous cytokines, like IL-15, to diseased tissues, minimizing systemic toxicity while enhancing immune responses locally; it serves oncology patients with poor responses to current therapies and plans expansion to autoimmune conditions.[1][2][3][5] In seed VC stage since its 2023 founding, backed by investors including Amplitude Ventures and Myeloma Investment Fund, Reverb shows early momentum with a recent collaboration for lead candidate advancement and an AACR 2025 poster presentation signaling preclinical progress toward clinical trials within two years.[1][4]
Founded in 2023 in Vancouver, Canada, Reverb Therapeutics emerged from the vision of biotech veterans addressing limitations in cytokine therapies for cancer and immune diseases.[1][2][4] David De Graaf, PhD, co-founder, President, and CEO, brings extensive experience from leading Abcuro, Comet Therapeutics, and Syntimmune, plus roles at Apple Tree Partners, Flagship Pioneering, Pfizer, AstraZeneca, and Boehringer Ingelheim.[3][4] Surjit Dixit, PhD, co-founder and Chief Scientific Officer, leads the scientific efforts.[2][4] The idea stemmed from amplifying the body's natural immune mechanisms—particularly cytokines like IL-15—to boost therapies like PD-1 inhibitors (e.g., Keytruda) without foreign agents, gaining early traction through seed funding and a November 2024 partnership with Royalmount Laboratories for pre-IND work on its first candidate.[1][3][4]
Reverb rides the bispecific antibody and cytokine therapy wave in immuno-oncology, where limitations like toxicity and poor penetration in solid tumors create unmet needs for next-gen treatments.[1][3] Timing aligns with surging demand for targeted immunotherapies amid PD-1/PD-L1 dominance, as combos seek deeper responses in resistant cancers; market forces favor platforms using endogenous signals for safety and manufacturability.[2][3] By localizing cytokines, Reverb influences the ecosystem toward precise, body-native modulation, potentially expanding to autoimmunity and integrating with standards like Keytruda, accelerating Canada's biotech hub via local CRO collaborations.[1][4]
Reverb's preclinical momentum positions it for lead selection and IND filing in 2025-2026, with AMP-01 potentially entering trials soon to validate synergy with PD-1s.[1][3] Trends like AI-driven antibody design and combo immuno-oncology will shape progress, alongside autoimmune expansion via AMP-03.[4][5] Influence may grow through partnerships, scaling its platform to redefine cytokine utility beyond toxicity barriers—echoing its core mission to harness natural immunity for transformative therapies.[2][3]
Reverb Therapeutics has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $12.0M Seed | Amplitude VC |